Bionet (1784) — Cash Flow Reinvestment Rate

Latest as of June 2026: 1.19x

Bionet (1784) has a Cash Flow Reinvestment Rate of 1.19x as of June 2026, reinvesting NT$60.75 Million (capex NT$10.14 Million plus investments NT$-50.60 Million) from operating cash flow of NT$51.22 Million. See 1784 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

1.19x
(Capex + Investments) / Operating CF

Total Reinvested

NT$60.75 Million
Capex + Investments

Operating Cash Flow

NT$51.22 Million
TWD

Capital Expenditures

NT$10.14 Million
TWD

Bionet Cash Flow Reinvestment Rate (2019–2025)

Historical reinvestment intensity for Bionet across 7 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Bionet.

Annual Cash Flow Reinvestment Rate for Bionet (2019–2025)

Year-by-year capital reinvestment analysis for Bionet. See 1784 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2025 2.04x NT$302.51 Million NT$148.04 Million NT$132.18 Million ▼ -53.3%
2024 4.38x NT$772.28 Million NT$176.49 Million NT$103.49 Million ▲ +53.6%
2023 2.85x NT$436.21 Million NT$153.09 Million NT$26.28 Million ▲ +653.0%
2022 0.38x NT$35.82 Million NT$94.65 Million NT$32.91 Million ▼ -82.4%
2021 2.15x NT$29.80 Million NT$13.88 Million NT$16.66 Million ▲ +101.9%
2020 1.06x NT$78.35 Million NT$73.66 Million NT$38.03 Million ▼ -95.0%
2019 21.27x NT$56.78 Million NT$2.67 Million NT$11.60 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow